The latest price target for NeuroOne Medical Tech (NASDAQ:NMTC) was reported by Alliance Global Partners on August 15, 2023. The analyst firm set a price target for $2.20 expecting NMTC to rise to within 12 months (a possible 190.16% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for NeuroOne Medical Tech (NASDAQ:NMTC) was provided by Alliance Global Partners, and NeuroOne Medical Tech maintained their buy rating.

There is no last upgrade for NeuroOne Medical Tech

The last downgrade for NeuroOne Medical Technologies Corp happened on March 28, 2022 when Craig-Hallum changed their price target from N/A to N/A for NeuroOne Medical Technologies Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeuroOne Medical Tech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeuroOne Medical Tech was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.

While ratings are subjective and will change, the latest NeuroOne Medical Tech (NMTC) rating was a maintained with a price target of $3.25 to $2.20. The current price NeuroOne Medical Tech (NMTC) is trading at is $0.76, which is out of the analyst’s predicted range.